Lexagene Holdings (CVE: LXG- OTCQB: LXXGF) CEO Jack Regan joined Steve Darling from Proactive with news the company is planning to use their patented MiQLa system to investigate novel variants of the SARS-Cov-2 which is the pathogen that causes COVID-19.
Dr. Regan telling Proactive this investigation of the variants becomes very important to make sure vaccines will remain effective as the new strains appear to be about 70% more contagious, making containment that much more challenging.
Price: 1.25 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Health
Retail & consumer
Genel Energy PLC's (LON:GENL), Bill Higgs speaks to Proactive London about their latest trading and operational result. Higgs explains how 2020, despite being a tough year, 'set the foundation for what's ahead', and now in a position to grow in 2021, with a twelve-well drill campaign among...
Health
ReNeuron Group completes first dosing of patients in study for new...
Retail & consumer
One Media iP Group adds more strings to their bow, acquiring...
Prev article
